SutherlandMSSandersonRJGordonKA. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem2006; 281: 10540–10547.
2.
FranciscoJACervenyCGMeyerDL. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood2003; 102: 1458–1465.
3.
SenterPDSieversEL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol2012; 30: 631–637.
BaldoBA. Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. Oncoimmunology2013; 2: e26333–e26333.
6.
BaxleyAAKummDEBishopCB. Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantation. J Oncol Pharm Pract2013; 19: 279–283.
7.
YounesABartlettNLLeonardJP. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med2010; 363: 1812–1821.
8.
FanaleMAForero-TorresARosenblattJD. A phase 1 weekly dosing study of brentuximab vetodin in patients with relapsed/refractory CD30-positive hematological malignancies. Clin Can Res2012; 18: 248–255.
9.
BrennanPJBouzaTRHsuFI. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol2009; 124: 1259–1266.
10.
HongDIBankovaLCahillKN. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol2012; 8: 43–54.
11.
De VitaMDEvensAMRosenST. Multiple successful desentizations to brentuximab vedotin: a case report and literature review. J Natl Compr Canc Netw2014; 12: 465–471.
